Absci (ABSI) 3rd Annual Guggenheim Healthcare Innovation Conference summary
Event summary combining transcript, slides, and related documents.
3rd Annual Guggenheim Healthcare Innovation Conference summary
10 Nov, 2026Pipeline strategy and ABS-201
Strategy has shifted from an AI drug-creation platform working with pharma partners to an owner of antibody programs; ABS-201 is the lead asset in Phase I/IIa for pattern hair loss and endometriosis.
ABS-201 blocks the prolactin receptor; the proposed hair-cycle effect is to move follicles from regression into active growth, while prolactin may contribute to endometriosis lesion formation and pain.
The target profile for pattern hair loss is 2–3 injections over six months, with potential multi-year durability after treatment ends; this remains a development goal, supported by preclinical macaque observations.
Pattern hair loss trial and readouts
The Phase I/IIa HEADLINE study’s SAD data, released in June, showed generally safe and tolerable results; half-life supported the intended extended dosing interval, and MAD is ongoing.
MAD has three planned cohorts of 49 participants at 300 mg, 600 mg and 1,200 mg, with double-blind, placebo-controlled 3:1 randomization.
A male-only 13-week interim analysis is expected next month; it will include target-area non-vellus hair count, total hair count and target-area hair width, with more participants from earlier than later cohorts.
The 13-week goal is a directionally positive hair-growth signal; the 26-week proof-of-concept readout is expected early next year, with a stronger result sought and additional patient-reported, image and other measures.
Results are planned by dose cohort and placebo while the study remains blinded; hair darkening or pigmentation is an exploratory potential benefit, not included in current assumptions.
Separate female cohorts will generate later datasets; the proposed targeted mechanism is not expected to cause unwanted hair growth, which could distinguish it from some existing options.
Endometriosis program
Hope Medicine’s HMI-115 data showed reduced dysmenorrhea at the high dose, viewed as proof-of-concept support; planned design refinements include a two-cycle run-in and broader geographic and ethnic diversity.
Phase II is planned to start in the middle of next year; the contemplated study is subject to finalization and may enroll 150 participants across 10+ countries, testing two or three doses.
Endometriosis endpoints are planned to include pain measures, including non-menstrual pain and dysmenorrhea; ABS-201 may also affect lesion growth and could be disease-modifying.
Management sees potential for a second-line role amid treatment trade-offs and estimates peak sales above $4B; endometriosis dosing is likely to differ from pattern hair loss dosing.
Latest events from Absci
- ABS-201 readouts approach as $173.7M liquidity supports projected runway into H2 2028.ABSI
Q3 2026 - ABS-201 advances toward pattern hair loss proof of concept as AI design capabilities expand.ABSI
Corporate presentation - ABS-201 advances with strong safety, high demand, and pivotal data expected in December.ABSI
Morgan Stanley 24th Annual Global Healthcare Conference - AI-driven clinical programs advance toward key milestones, supported by robust cash reserves.ABSI
H.C. Wainwright 28th Annual Global Investment Conference - AI-driven antibody platform advances novel therapies for hair loss and endometriosis, targeting large markets.ABSI
Corporate presentation - Positive interim data and strong cash reserves support continued clinical and pipeline progress.ABSI
Q2 2026 - AI-powered drug discovery advances key assets toward pivotal clinical milestones and partnerships.ABSI
Morgan Stanley 23rd Annual Global Healthcare Conference - AI-driven antibody platform advances ABS-101 and ABS-201 toward major clinical milestones.ABSI
R&D Day 2024 - Generative AI-driven antibody design, AMD partnership, and pipeline milestones set stage for 2025.ABSI
43rd Annual J.P. Morgan Healthcare Conference 2025